인도네시아의 의료 물류 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the Indonesia healthcare logistics market size was valued at USD 5.23 billion in 2025 and is estimated to grow from USD 5.69 billion in 2026 to reach USD 8.57 billion by 2031, at a CAGR of 8.56% during the forecast period from 2026 to 2031.

Indonesia's island geography makes dependable pharmaceutical distribution difficult, especially when a shipment needs to move between road, port, sea, airport, and local delivery networks. This report is Segmented by Logistics Function (Transportation, Warehousing, and More), by Temperature (Temperature, Non-Temperature), by Product Type (Pharmaceuticals, Vaccines, and More), by Destination (Domestic, International), by End User (Hospitals and Clinics, Biopharmaceutical, and More), and by Region (Java, Sumatra, and More). The Market Forecasts are Provided in Terms of Value (USD).

Indonesia Healthcare Logistics Market Trends and Insights

Expansion of Healthcare Access Increasing Pharmaceutical Logistics Demand

JKN had near-universal enrollment in 2025, covering 98% of Indonesia's population, or 280 million members. This coverage links medicine volumes closely to public healthcare access across Indonesia's provinces, where facilities depend on regular delivery schedules within the Indonesia healthcare logistics market. Each new community health center and hospital requires repeated replenishment of drugs, devices, vaccines, diagnostics, and other healthcare supplies, often through scheduled distribution arrangements that must remain reliable throughout the year. The 2026 health allocation of IDR 244 trillion (USD 13.75 billion), including IDR 69 trillion (USD 3.89 billion) for JKN contributions, provided a public funding base for treatment, medicine supply, and service delivery across the national healthcare system. JKN's claim ratio reached 111.8% in February 2026, indicating higher treatment use while raising questions about program finances. For the Indonesia healthcare logistics market, greater use of treatment services means more frequent pharmaceutical movements through national and regional delivery networks.

Biologics, Vaccines, and Advanced Therapies Driving Cold Chain Demand

Vaccines, biosimilars, oncology injectables, and plasma-derived therapies require validated chilled, frozen, or ultra-low-temperature handling. This requirement raises the value of specialized storage, packaging, monitoring, and airfreight services in the Indonesia healthcare logistics market, where cold-chain failures can affect product usability. BPOM Regulation No. 20/2025 strengthened cold-chain oversight for biological products and vaccines, raising operational requirements for providers handling these shipments. Daewoong Pharmaceutical Indonesia received BPOM GMP certification in September 2025 for autologous stem cells, NK cells, and exosomes at its Cikarang facility. Local production of advanced therapies creates demand for dedicated cryogenic transport routes, specialist packaging, trained handling teams, and documented control throughout each movement that conventional general-cargo providers cannot readily offer. The World Bank's USD 850 million Program-for-Results supporting JKN health access from 2025 to 2029 also supports the movement of specialty medicines through the Indonesian healthcare logistics market.

Archipelagic Infrastructure Gaps Increasing Inter-Island Logistics Costs

Indonesia has more than 17,000 islands, with nearly 7,000 inhabited, and this geography requires multimodal movement for many healthcare shipments. Goods often travel by road to a port, by sea to another island, and then by road or air to the final destination. Every transfer adds time, handling, potential temperature-control risk, and a need for clearer responsibility between parties in the Indonesia healthcare logistics market, particularly when products move through remote routes. A 2024 PLOS Global Public Health study reported that Maluku had 29 seaports and 14 vessels serving 24 inter-island routes, with single trips averaging 15 days. These transit periods are unsuitable for products with short stability windows, including some cell therapies. Addressing these gaps requires investment in port links, cold-chain warehousing, and buffer-stock systems, which may deter operators that cannot support long payback periods.

Other drivers and restraints analyzed in the detailed report include:

1. SATUSEHAT Logistics Integration Improving National Healthcare Visibility
2. Rising E-Pharmacy Demand Accelerating Time-Sensitive Healthcare Deliveries
3. Uneven Power Reliability Constraining Cold-Chain Service Continuity

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Transportation held 46.34% of Indonesia healthcare logistics market share in 2025, while value-added services and others are forecast to record a 10.34% CAGR through 2031, reflecting the continued importance of physical pharmaceutical movement alongside increasing demand for specialized logistics services. Transportation connects manufacturing sites, distributors, hospitals, clinics, retail pharmacies, and community health centers across varied local transport conditions. Warehousing and distribution provide the storage, consolidation, order preparation, and handoff control required to support these movements. Value-added services include track-and-trace support, repackaging, cold-chain monitoring, and regulatory documentation. CDOB 2025 further increased the importance of providers who integrated these activities into routine logistics operations.

Road transport remains central to intra-island distribution on Java and Sumatra, while sea and inland waterways support bulk freight and connections to outer-island hubs. Air cargo is used for urgent, high-value shipments, including biologics, clinical trial materials, and certain cell and gene therapy products with strict timing requirements. Rail has a limited but developing role in Java for selected urban corridors. Government-linked distribution contracts also require real-time tracking, GDP-compliant storage, inventory management, and multi-temperature handling across subnational delivery points. The Indonesia healthcare logistics market increasingly requires operators to combine physical transportation with information management, compliance, and specialized handling across national, regional, and local distribution networks.

Non-temperature controlled logistics held 56.38% of Indonesia healthcare logistics market size in 2025, while temperature controlled logistics is projected to record an 11.93% CAGR through 2031, reflecting the continued dominance of ambient healthcare products alongside rising demand for specialized cold-chain services. Tablets, capsules, over-the-counter drugs, and ambient-stable medical devices remain major product flows and require secure storage, controlled handling, inventory management, and reliable delivery even without refrigeration. Temperature-controlled logistics support biologics, biosimilars, vaccines, and advanced therapies that require defined temperature ranges throughout storage and transportation. Chilled handling from 0 °C to 5 °C supports insulin and conventional biologics, while deep-frozen and ultra-low-temperature conditions are required for products with more demanding storage requirements. Cell and gene therapies can require liquid-nitrogen conditions from -150 °C to -196 °C, creating specialized requirements for qualified equipment, validated packaging, and trained personnel.

BPOM Regulation No. 20/2025 further increased operational requirements for cold-chain logistics through quality risk management assessments, temperature-excursion procedures, ALCOA++ documentation, and automatic alarm systems. These requirements increase adaptation costs for wholesalers and distributors that lack validated equipment, trained teams, documented processes, alarm systems, temperature records, and consistent deviation-review procedures. The growing use of active temperature-controlled containers also indicates increasing demand for specialized pharmaceutical logistics capabilities, while planned national pharmaceutical infrastructure in Tangerang signals continued investment in cold-chain capacity. The Indonesia healthcare logistics market, therefore, increasingly requires providers to combine temperature-controlled transportation and storage with validated packaging, monitoring systems, documentation, and regulatory compliance.

Complete Report Scope:

• By Logistics Function
  • Transportation
    • Road
    • Air
    • Sea and Inland Waterways
    • Rail
  • Warehousing & Distribution
  • Value-added Services and Others
• By Temperature Type
  • Temperature Controlled
    • Chilled (0-5 °C)
    • Frozen (-18-0 °C)
    • Ambient
    • Deep-Frozen / Ultra-Low (less than-20 °C)
  • Non-Temperature Controlled
• By Product Type
  • Pharmaceuticals
    • Prescription & Speciality Drugs
    • OTC Drugs
  • Biopharmaceuticals (Biologics and Biosimilars)
  • Vaccines
  • Clinical Trial Materials
  • Cell and Gene Therapies
  • Medical Devices
  • Veterinary Medicine
  • Blood, Plasma & Blood Components
  • Diagnostic and Laboratory Products
  • Organs & Human Tissues
  • Others
• By Destination
  • Domestics
  • International
• By End User
  • Pharmaceutical Manufacturers
  • Biopharmaceutical Manufacturers
  • Hospitals & Clinics
  • Hospitals and Retail Pharmacies
  • Healthcare Distributors and Wholesalers
  • Others
• By Region
  • Java (Jakarta and BOD)
  • Sumatra
  • Kalimantan
  • Sulawesi
  • Bali and Nusa Tenggara
  • Papua Region and Maluku Islands

List of Companies Covered in this Report:

1. PT Anugerah Pharmindo Lestari
2. PT Enseval Putera Megatrading Tbk
3. PT Parit Padang Global
4. PT Anugrah Argon Medica
5. PT Kimia Farma Trading & Distribution
6. DHL Group
7. Kuehne+Nagel International AG
8. DSV A/S
9. CEVA Logistics
10. United Parcel Service, Inc.
11. FedEx
12. NX Group
13. PT Jasa Angkasa Semesta Tbk
14. Expeditors International
15. A.P. Moller - Maersk
16. Kiat Ananda Group
17. MGM Bosco Logistics
18. PT Sarana Mulya Logistik
19. PT Millennium Pharmacon International Tbk
20. PT Rajawali Nusindo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

• 3.1 Market Size, Growth, and Forecast Outlook
• 3.2 Key Demand Drivers and Healthcare Logistics Trends
• 3.3 Major Distribution Hubs and Demand Concentration
• 3.4 Competitive Landscape and Leading Healthcare Logistics Providers

4 MARKET LANDSCAPE

• 4.1 Market Overview & Role of Logistics in Healthcare
• 4.2 Healthcare Spending Trends
• 4.3 Market Drivers
  • 4.3.1 Expansion of Healthcare Access Increasing Pharmaceutical Logistics Demand
  • 4.3.2 Biologics, Vaccines, Advanced Therapies Driving Cold Chain Demand
  • 4.3.3 Outsourcing Non-Core Logistics Boosting GDP-Compliant Service Adoption
  • 4.3.4 SATUSEHAT Logistics Integration Improving National Healthcare Visibility
  • 4.3.5 Inter-Island Micro-Hubs Expanding Temperature-Controlled Delivery Network Reach
  • 4.3.6 Rising E-Pharmacy Demand Accelerating Time-Sensitive Healthcare Deliveries
• 4.4 Market Restraints
  • 4.4.1 Archipelagic Infrastructure Gaps Increasing Inter-Island Logistics Costs
  • 4.4.2 Compliance Requirements Increasing Specialized Capex and Staffing Costs
  • 4.4.3 Multiple Handoffs Increasing Temperature Excursion and Spoilage Risks
  • 4.4.4 Uneven Power Reliability Constraining Cold-Chain Service Continuity
• 4.5 Regulatory Framework for Healthcare Logistics Operations
• 4.6 Healthcare Supply Chain and Distribution Network Analysis
• 4.7 Technology Innovation and Digital Logistics Outlook
• 4.8 Evolution of Healthcare Logistics Requirements
• 4.9 Pharmaceutical Distribution Network and Cargo Flow Analysis
• 4.10 Cold Chain Capacity and Infrastructure Development Analysis
• 4.11 Healthcare Warehousing and Distribution Hub Network Analysis
• 4.12 Porter's Five Forces Analysis
  • 4.12.1 Threat of New Entrants
  • 4.12.2 Bargaining Power of Suppliers
  • 4.12.3 Bargaining Power of Buyers
  • 4.12.4 Threat of Substitutes
  • 4.12.5 Rivalry Among Competitors
• 4.13 Impact of Geo-Political Events on Supply Chain Shifts

5 MARKET SIZE AND GROWTH FORECASTS

• 5.1 By Logistics Function
  • 5.1.1 Transportation
    • 5.1.1.1 Road
    • 5.1.1.2 Air
    • 5.1.1.3 Sea and Inland Waterways
    • 5.1.1.4 Rail
  • 5.1.2 Warehousing & Distribution
  • 5.1.3 Value-added Services and Others
• 5.2 By Temperature Type
  • 5.2.1 Temperature Controlled
    • 5.2.1.1 Chilled (0-5 °C)
    • 5.2.1.2 Frozen (-18-0 °C)
    • 5.2.1.3 Ambient
    • 5.2.1.4 Deep-Frozen / Ultra-Low (less than-20 °C)
  • 5.2.2 Non-Temperature Controlled
• 5.3 By Product Type
  • 5.3.1 Pharmaceuticals
    • 5.3.1.1 Prescription & Speciality Drugs
    • 5.3.1.2 OTC Drugs
  • 5.3.2 Biopharmaceuticals (Biologics and Biosimilars)
  • 5.3.3 Vaccines
  • 5.3.4 Clinical Trial Materials
  • 5.3.5 Cell and Gene Therapies
  • 5.3.6 Medical Devices
  • 5.3.7 Veterinary Medicine
  • 5.3.8 Blood, Plasma & Blood Components
  • 5.3.9 Diagnostic and Laboratory Products
  • 5.3.10 Organs & Human Tissues
  • 5.3.11 Others
• 5.4 By Destination
  • 5.4.1 Domestics
  • 5.4.2 International
• 5.5 By End User
  • 5.5.1 Pharmaceutical Manufacturers
  • 5.5.2 Biopharmaceutical Manufacturers
  • 5.5.3 Hospitals & Clinics
  • 5.5.4 Hospitals and Retail Pharmacies
  • 5.5.5 Healthcare Distributors and Wholesalers
  • 5.5.6 Others
• 5.6 By Region
  • 5.6.1 Java (Jakarta and BOD)
  • 5.6.2 Sumatra
  • 5.6.3 Kalimantan
  • 5.6.4 Sulawesi
  • 5.6.5 Bali and Nusa Tenggara
  • 5.6.6 Papua Region and Maluku Islands

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Key Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Geographic Coverage, Products and Services, Recent Developments)
  • 6.4.1 PT Anugerah Pharmindo Lestari
  • 6.4.2 PT Enseval Putera Megatrading Tbk
  • 6.4.3 PT Parit Padang Global
  • 6.4.4 PT Anugrah Argon Medica
  • 6.4.5 PT Kimia Farma Trading & Distribution
  • 6.4.6 DHL Group
  • 6.4.7 Kuehne+Nagel International AG
  • 6.4.8 DSV A/S
  • 6.4.9 CEVA Logistics
  • 6.4.10 United Parcel Service, Inc.
  • 6.4.11 FedEx
  • 6.4.12 NX Group
  • 6.4.13 PT Jasa Angkasa Semesta Tbk
  • 6.4.14 Expeditors International
  • 6.4.15 A.P. Moller - Maersk
  • 6.4.16 Kiat Ananda Group
  • 6.4.17 MGM Bosco Logistics
  • 6.4.18 PT Sarana Mulya Logistik
  • 6.4.19 PT Millennium Pharmacon International Tbk
  • 6.4.20 PT Rajawali Nusindo

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space Opportunities and Unmet Healthcare Logistics Needs
• 7.2 High-Potential Healthcare Segments and Growth Opportunities
• 7.3 Strategic Growth Priorities Across Healthcare Logistics Ecosystem
• 7.4 Future Market Outlook and Emerging Healthcare Demand Pockets